Camp4 Therapeutics (CAMP) Interest Expenses (2023 - 2024)
Camp4 Therapeutics recorded quarterly Interest Expenses of -$145000.0 in Q4 2024, down 333.87% quarter-over-quarter from $62000.0 in Q3 2024, and down 274.7% year-over-year from $83000.0 in Q1 2024.
Camp4 Therapeutics' Interest Expenses history runs 2 years deep, the most recent figure standing at -$145000.0 for Q4 2024.
- In Q4 2024, Interest Expenses fell 274.7% year-over-year to -$145000.0; the TTM figure through Sep 2025 stood at -$145000.0 (down 200.0% YoY), while the FY2025 annual figure was $192000.0, up 481.82% from the prior year.
- Interest Expenses came in at -$145000.0 for Q4 2024 at Camp4 Therapeutics, down from $62000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $83000.0 in Q4 2023 to a low of -$145000.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Camp4 Therapeutics | 245.89 Mn | 245.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -145,000.00 |
| Dec 31, 2024 | -145,000.00 |
| Sep 30, 2024 | 62,000.00 |
| Sep 30, 2024 | 62,000.00 |
| Dec 31, 2023 | 83,000.00 |
| Dec 31, 2023 | 83,000.00 |
| Sep 30, 2023 | 47,000.00 |
| Sep 30, 2023 | 47,000.00 |